What is Tibsovo used to treat?

Tibsovo (ivosidenib) is used to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) who have an isocitrate dehydrogenase-1 (IDH1) genetic mutation.

Tibsovo is used in patients with AML with an IDH1 mutation in:

• adults with newly diagnosed AML who are 75 years or older or who have health problems that prevent the use of certain chemotherapy treatments.
• adults with AML when the disease has come back or has not improved after previous treatment(s).

Tibsovo was the first drug approved in the IDH1 inhibitor class. It is approved for use with an FDA-approved companion diagnostic that is used to detect specific mutations in the IDH1 gene in patients with AML.